CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, published by BEGELL HOUSE INC, serves as a vital resource within the fields of Genetics and Molecular Biology. With the ISSN 1045-4403 and E-ISSN 2162-6502, this journal has been contributing to scientific discourse since 1990 and is projected to continue its publication until 2024. Despite its classification in the Q3 quartile for both Genetics and Molecular Biology, its impact on the research community is significant, as evidenced by its diverse range of critical reviews that synthesize and analyze emerging trends and foundational studies in gene expression. The journal, located in the United States at 50 North St, Danbury, CT 06810, offers a platform for researchers, professionals, and students to engage with innovative ideas and methodologies that drive forward the understanding of gene regulatory mechanisms in eukaryotes. Although it currently does not offer open access, the journal's content remains crucial for those dedicated to advancing knowledge in the intricacies of genetic expression.

MOLECULAR BIOLOGY, published by PLEIADES PUBLISHING INC, serves as a vital repository for the dissemination of innovative research within the fields of biochemistry, genetics, and molecular biology. With an ISSN of 0026-8933 and an E-ISSN of 1608-3245, this journal has been a mainstay in the scientific community since its inception, embracing its deep historical roots from 1971 to the present. Recognized for its qualitative contributions, MOLECULAR BIOLOGY is ranked in the Q3 quartile for Biophysics and Q4 for Structural Biology, placing it among select journals in its domain. Researchers and students alike benefit from its rigorous peer-reviewed articles, which focus on all aspects of molecular mechanisms and interactions. The journal's inclusion in prestigious databases underlines its commitment to academic excellence. The editorial board is dedicated to fostering the sharing of influential findings, making it an essential resource for advancing knowledge and innovation in molecular biology.

GENOME BIOLOGY is a premier, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genomics, molecular biology, and bioinformatics. Accessible as an Open Access journal since 2000, it aims to disseminate high-quality, cutting-edge research that contributes to our understanding of genome biology's intricate mechanisms. The journal boasts an impressive impact, ranking 8th in Agricultural and Biological Sciences and 9th in Biochemistry, Genetics and Molecular Biology, highlighting its significance among scholars, professionals, and students alike. With a commitment to facilitating the exchange of invaluable scientific knowledge, GENOME BIOLOGY provides an important platform for discussions on evolutionary biology, genetic systems, and cell biology, contributing to the advancement of these dynamic disciplines.

RNA Biology is a premier journal published by Taylor & Francis Inc, focusing on the intricate and evolving field of RNA research. With an ISSN of 1547-6286 and E-ISSN of 1555-8584, this journal has established itself as an essential resource for professionals, researchers, and students engaged in both molecular and cell biology. Recognized in the 2023 quartile rankings, RNA Biology holds a distinguished Q1 category in Molecular Biology and a Q2 category in Cell Biology, indicative of its significant impact and reputation within the scientific community. The journal emphasizes the importance of RNA in various biological processes, highlighting both fundamental and applied aspects, which is crucial for advancing our understanding of gene expression and regulation. With a strong Scopus ranking, including Rank #105/410 in Molecular Biology and Rank #83/285 in Cell Biology, RNA Biology is not just a publication but a vital platform for sharing groundbreaking findings and insights into RNA research. With a convergence that spans from 2004 to 2024, the journal promises to continue its legacy of excellence in disseminating important discoveries in RNA science, contributing richly to ongoing scientific dialogue and innovation.

GENES TO CELLS is a distinguished peer-reviewed journal published by Wiley, offering valuable insights into the intricate world of cell biology and genetics. With an ISSN of 1356-9597 and an E-ISSN of 1365-2443, this journal has been contributing to the academic community since its inception in 1996 and will continue its publishing journey until 2024. Recognized with a category quartile ranking of Q3 in both Cell Biology and Genetics, and Q2 in Medicine (Miscellaneous) as of 2023, it serves as an important platform for disseminating innovative research and reviews in molecular biology and related fields. Although it does not currently offer open access, the journal caters to a diverse readership by providing comprehensive studies that are essential for professionals, researchers, and students aiming to deepen their understanding of genetic mechanisms and cellular functions. Situated in the United Kingdom, GENES TO CELLS continues to play a pivotal role in shaping the future of biological research.

EMBO REPORTS, published by WILEY, is a premier journal in the fields of Biochemistry, Genetics, and Molecular Biology, recognized for its rigorous peer-review process and impactful scientific contributions. Established in the year 2000 in the United Kingdom, this journal has maintained a stellar reputation, reflected in its consistent positioning within the Q1 category across these disciplines as of 2023. EMBO REPORTS excels in disseminating high-quality and timely research that addresses fundamental questions and challenges in molecular biology and genetics, making it an invaluable resource for researchers, professionals, and students. With impressive Scopus rankings, including Genetics at the 32nd rank and a 90th percentile placement, it fosters an environment for scholarly exchange and advances in knowledge. While Open Access options are not available, the journal continues to enhance its impact through traditional subscription models, thereby maintaining wide visibility in the scientific community. Its ongoing evolution promises continued relevance and influence until at least 2024.

The EMBO JOURNAL, published by Wiley in Germany, is a renowned scientific journal that has been at the forefront of research in the fields of biochemistry, genetics, and molecular biology since its inception in 1982. With an impressive convergence of contributions leading up to 2024, this journal is recognized for its high impact, reflected in its Q1 rankings across multiple categories including Immunology, Molecular Biology, and Neuroscience. It holds a prestigious place in the academic community, standing out with an exemplary Scopus ranking of #3 in General Immunology and Microbiology and #6 in General Neuroscience, making it a critical resource for researchers, professionals, and students alike. The journal aims to publish transformative research that sheds light on the underlying mechanisms of biological processes, thus advancing our understanding of health and disease. While currently not offering open access, the EMBO JOURNAL continues to facilitate a rich exchange of knowledge through its rigorous peer-review process and commitment to excellence.

CHROMOSOMA is a prestigious journal dedicated to advancing the field of genetics, published by Springer in Germany. With an ISSN of 0009-5915 and an E-ISSN of 1432-0886, this journal has been a cornerstone in the publishing landscape since its inception in 1939, serving as a critical resource for researchers and professionals interested in the intricacies of chromosomal biology. Although it operates on a subscription basis, the journal's rigorous peer-review process ensures the dissemination of high-quality research findings. With a commendable Q2 ranking in both genetic and clinical genetics categories as of 2023, CHROMOSOMA aims to bridge theoretical concepts with practical applications in medicine and biology. Researchers will appreciate its relevance, as indicated by its Scopus ranks and integration of diverse topics ranging from molecular genetics to clinical implications. By fostering collaboration and knowledge-sharing among scholars, CHROMOSOMA continues to shape the future of genetic research.

NUCLEIC ACIDS RESEARCH, published by Oxford University Press, is a premier peer-reviewed journal in the field of genetics, holding a prestigious Q1 ranking in this domain as of 2023. Since its inception in 1974 and with a converged publication horizon extending to 2024, this journal has established itself as a vital resource for researchers and professionals interested in the molecular aspects of nucleic acids, encompassing DNA and RNA studies as well as their implications in biochemistry and molecular biology. With an impressive Scopus rank of #6 out of 347 in Genetics, this journal is positioned in the 98th percentile among its peers, highlighting its significant impact and relevance in the scientific community. As an open access journal since 2005, NUCLEIC ACIDS RESEARCH ensures wide dissemination of knowledge, promoting collaborative advancements in genetic research. For those looking to stay at the forefront of nucleic acid research, this journal remains an essential publication for accessing cutting-edge findings and innovative methodologies in the field.

Clinical Epigenetics is a pioneering open-access journal published by BMC, dedicated to advancing the field of epigenetics and its critical implications in clinical and translational research. Established in 2011, the journal has become an authoritative resource in the realms of developmental biology, genetics, and molecular biology, as evidenced by its impressive 2023 Scopus categorization as a Q1 journal in multiple domains including clinical genetics. With a robust impact factor and rankings that place it among the top quartiles in its fields—Rank #13 in Clinical Genetics and #14 in Developmental Biology—Clinical Epigenetics serves as an essential platform for researchers, professionals, and students alike, encouraging the dissemination of high-quality research findings. Operating from its United Kingdom headquarters, this journal not only contributes to scholarly dialogue across the globe but also supports unrestricted access to vital findings that push the boundaries of our understanding of epigenetic mechanisms and their clinical applications.